银屑病关节炎患者接受治疗时恶性肿瘤发生风险:一项系统评价与Meta分析
该系统评价与Meta分析纳入9项队列研究、共43115例接受治疗的银屑病关节炎(PsA)患者,评估治疗与恶性肿瘤风险的关系。结果显示,与一般人群相比,接受治疗的PsA患者总体恶性肿瘤风险升高(合并RR 1.29,95%CI 1.04-1.60),异质性高(I2=71.37%);亚组分析中csDMARDs治疗者癌症风险升高(合并RR 1.75,95%CI 1.40-2.18),而bDMARDs治疗者未见升高(合并RR 0.957,95%CI 0.80-1.14)。
要点
- 接受治疗的PsA患者总体恶性肿瘤风险较一般人群升高(合并RR 1.29,95%CI 1.04-1.60)。
- csDMARDs治疗者癌症风险升高(合并RR 1.75,95%CI 1.40-2.18),bDMARDs治疗者未见升高(合并RR 0.957,95%CI 0.80-1.14)。
- 接受治疗的PsA患者非黑色素瘤皮肤癌风险较对照升高(合并RR 2.46,95%CI 1.84-3.28)。
核心结论
- 接受治疗的银屑病关节炎患者总体恶性肿瘤风险较一般人群升高,非黑色素瘤皮肤癌风险亦升高。
- csDMARDs治疗者癌症风险升高,bDMARDs治疗者未见升高。
- 作者认为需要大规模纵向研究才能就PsA治疗相关恶性肿瘤风险得出确切结论。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、EMBASE和Web of Science数据库以识别相关研究和试验。
- 共纳入9项队列研究,合计43115例接受治疗的银屑病关节炎患者。
- 使用STATA 11.2软件进行统计分析。
主要发现
- 与一般人群参照组相比,接受治疗的PsA患者总体恶性肿瘤风险呈显著正相关(合并RR 1.29,95%CI 1.04-1.60),异质性高(I2=71.37%)。
- 亚组分析中,接受csDMARDs治疗的PsA患者癌症风险升高(合并RR 1.75,95%CI 1.40-2.18)。
- 接受bDMARDs治疗的PsA患者癌症风险未见升高(合并RR 0.957,95%CI 0.80-1.14)。
- 与对照相比,接受治疗的PsA患者非黑色素瘤皮肤癌风险升高(合并RR 2.46,95%CI 1.84-3.28)。
关键数值与推荐
- 总体恶性肿瘤:合并RR 1.29(95%CI 1.04-1.60),异质性I2=71.37%。
- csDMARDs亚组癌症风险:合并RR 1.75(95%CI 1.40-2.18)。
- bDMARDs亚组癌症风险:合并RR 0.957(95%CI 0.80-1.14)。
- 非黑色素瘤皮肤癌:合并RR 2.46(95%CI 1.84-3.28)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 异质性高(I2=71.37%)。
- 作者认为需要大规模纵向研究才能就PsA治疗相关恶性肿瘤风险得出确切结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriatic arthritis (PsA) is a chronic and seronegative inflammatory arthritis occurring in patients with psoriasis. The current knowledge about the risk of malignancy associated with psoriatic arthritis (PsA) patients undergoing therapy is controversial. We focused on the relationship between malignancy and therapy and undertook a meta-analysis to address this issue. METHODS: A systematic literature search of the PubMed, EMBASE, and Web of Science databases was performed to identify relevant studies and trials. Statistical analysis was conducted using STATA 11.2 software. RESULTS: Nine cohort studies were included, corresponding to a total of 43,115 PsA patients undergoing therapy. A significant positive association between therapy and increased risk for overall malignancy was found relative to the general population as the reference group (pooled RR, 1.29; 95% CI: 1.04-1.60). High heterogeneity was found (I2 = 71.37%). Subgroup analysis reported that PsA patients treated with conventional synthetic disease modifying antirheumatic drugs (csDMARDs) presented increased cancer risk (pooled RR, 1.75; 95% CI: 1.40-2.18) but patients treated with biological disease modifying antirheumatic drugs (bDMARDs) did not (pooled RR, 0.957; 95% CI: 0.80-1.14). Compared to controls, patients with PsA undergoing treatment specifically are at increased risk for non-melanoma skin cancers (pooled RR, 2.46; 95% CI: 1.84-3.28). CONCLUSIONS: This study allowed the estimation of cancer risk in PsA patients during therapy. Large-scale longitudinal studies will be essential to draw firm conclusions regarding PsA-associated risk for treatment-induced malignancy.
引用
- Luo X, Deng C, Fei Y, et al. Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018. PMID: 29929736. doi:10.1016/j.semarthrit.2018.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。